In a filing, Beam Therapeutics Inc revealed its FMR LLC unloaded Company’s shares for reported $0.99 million on Jul 30 ’25. In the deal valued at $20.50 per share,48,374 shares were sold. As a result of this transaction, FMR LLC now holds 2,073,665 shares worth roughly $39.65 million.
Then, Simon Amy sold 876 shares, generating $17,625 in total proceeds. Upon selling the shares at $20.12, the Chief Medical Officer now owns 64,864 shares.
Before that, Simon Amy sold 374 shares. Beam Therapeutics Inc shares valued at $6,336 were divested by the Chief Medical Officer at a price of $16.94 per share. As a result of the transaction, Simon Amy now holds 65,740 shares, worth roughly $1.26 million.
BofA Securities upgraded its Beam Therapeutics Inc [BEAM] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who increased its forecast for the stock in early March from “a Sector perform” to “a Sector outperform”. Cantor Fitzgerald also remained covering BEAM and has increased its forecast on January 29, 2025 with a “an Overweight” recommendation from previously “Neutral” rating. Leerink Partners revised its rating on November 06, 2024. It rated BEAM as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of BEAM
On Monday, Beam Therapeutics Inc [NASDAQ:BEAM] saw its stock jump 1.54% to $19.12. Over the last five days, the stock has lost -8.21%. Beam Therapeutics Inc shares have fallen nearly -39.57% since the year began. Nevertheless, the stocks have fallen -22.90% over the past one year.
How much short interest is there in Beam Therapeutics Inc?
A steep rise in short interest was recorded in Beam Therapeutics Inc stocks on 2025-07-15, growing by 1.93 million shares to a total of 23.66 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 21.73 million shares. There was a rise of 8.16%, which implies that there is a positive sentiment for the stock.
